TALK vs. WGS, DCGO, INNV, PNTG, SHCR, PIII, USPH, RVNC, SLRN, and SRDX
Should you be buying Talkspace stock or one of its competitors? The main competitors of Talkspace include GeneDx (WGS), DocGo (DCGO), InnovAge (INNV), The Pennant Group (PNTG), Sharecare (SHCR), P3 Health Partners (PIII), U.S. Physical Therapy (USPH), Revance Therapeutics (RVNC), Acelyrin (SLRN), and Surmodics (SRDX). These companies are all part of the "medical" sector.
GeneDx (NASDAQ:WGS) and Talkspace (NASDAQ:TALK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
61.7% of GeneDx shares are owned by institutional investors. Comparatively, 57.4% of Talkspace shares are owned by institutional investors. 28.1% of GeneDx shares are owned by insiders. Comparatively, 18.4% of Talkspace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
GeneDx presently has a consensus target price of $18.00, suggesting a potential downside of 13.25%. Talkspace has a consensus target price of $3.00, suggesting a potential upside of 6.76%. Given GeneDx's higher probable upside, analysts clearly believe Talkspace is more favorable than GeneDx.
GeneDx received 3 more outperform votes than Talkspace when rated by MarketBeat users. Likewise, 42.86% of users gave GeneDx an outperform vote while only 0.00% of users gave Talkspace an outperform vote.
Talkspace has a net margin of -7.33% compared to Talkspace's net margin of -60.86%. GeneDx's return on equity of -10.02% beat Talkspace's return on equity.
Talkspace has lower revenue, but higher earnings than GeneDx. Talkspace is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
GeneDx has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Talkspace has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
In the previous week, Talkspace had 18 more articles in the media than GeneDx. MarketBeat recorded 19 mentions for Talkspace and 1 mentions for GeneDx. Talkspace's average media sentiment score of 1.89 beat GeneDx's score of 0.71 indicating that GeneDx is being referred to more favorably in the media.
Summary
GeneDx beats Talkspace on 10 of the 18 factors compared between the two stocks.
Get Talkspace News Delivered to You Automatically
Sign up to receive the latest news and ratings for TALK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TALK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talkspace Competitors List
Related Companies and Tools
